Type 1 Diabetes TrialNet
Study Participants Healthcare Professionals Researchers Locations Publications What is TrialNet? News and Events Get Screened! Home

Information for Study Participants

TrialNet Studies

TrialNet mainly conducts 3 types of studies:

1. Studies for people who do not have type 1 diabetes, but are at increased risk because they have a family member with the disease:

Study Status Description
Pathway to Prevention Study Recruiting

This study screens and observes relatives of people with type 1 diabetes to learn more about how the disease occurs

The Oral Insulin for Prevention of Type 1 Diabetes Study Recruiting This study tests whether a daily oral insulin capsule can prevent or delay the disease in at-risk relatives of people with type 1 diabetes

Anti-CD3 mAb (Teplizumab) for Prevention Of Diabetes In Relatives At Risk For Type 1 Diabetes Mellitus

www.preventT1d.com

Recruiting

This study tests whether teplizumab helps stop or slow down the autoimmune reaction that is destroying beta cells in people who are at high risk of developing type 1 diabetes.

CTLA4-Ig (Abatacept) for Prevention of Type 1 Diabetes in Relatives At-Risk

Recruiting

TrialNet is testing abatacept in persons determined to be at risk, but not yet diagnosed, to see if  it can help delay or prevent the onset of type 1 diabetes.

The Nutritional Intervention to Prevent Type 1 Diabetes Study No Longer Recruiting A pilot study testing whether docosahexaenoic acid (DHA), and omega-3 fatty acid found in some foods can prevent or delay the autoimmunity leading to type 1 diabetes

 

2. Studies for those recently diagnosed with type 1 diabetes (within 100 days):

Study Status Description
Effects of Low Dose ATG (Thymoglobulin®) Used Alone or in Combination with GCSF (Neulasta®) in New Onset Diabetes Not Yet Recruiting This study tests whether ATG used alone or in combination with GCSF will help people continue to make some of their own insulin
Anti IL-1Beta (Canakinumab) in Recent Onset Diabetes No Longer Recruiting This study tests whether repeated injections of an experimental medication called canakinumab will help people with newly-diagnosed type 1 diabetes continue to make some of their own insulin.
Metabolic Control in New Onset Diabetes No Longer Recruiting This study will look at whether early intensive glucose control can help preserve insulin production.
CTLA-4 Ig (Abatacept) in Recent Onset Diabetes

Study completed.

Click here to see a summary of study findings

Testing of the drug abatacept, which is already being used to treat rheumatoid arthritis, to try to protect remaining insulin production.

GAD in New Onset Type 1 Diabetes

Study completed.

Click here to see a summary of study findings

This study is exploring whether treatment with injections of the GAD protein can help preserve insulin production.
The Rituximab Study (Anti-CD20)

Study completed.

Click here to see a summary of study findings

This study is trying to see if it is possible to stop or slow down the immune system's attack in newly diagnosed type 1 diabetes patients so that the remaining beta cells can survive and keep making some of the insulin your body needs.
The MMF/DZB Study

Study completed.

Click here to see a summary of study findings

This study will examine whether a combination of two medicines can stop the immune system from destroying beta cells in new onset type 1 diabetes patients (within 3 months of diagnosis).

 

3. Studies for participants previously enrolled in TrialNet Studies

Study Status Description
Long-Term Investigative Follow-Up in TrialNet (LIFT) Study Recruiting
(NOTE: This study is open only to participants previously enrolled in a TrialNet study)

This study is monitoring people early in the disease process immediately following diagnosis, as well as provides follow-up to those previously enrolled in TrialNet new onset diabetes studies.

 

Type 1 Diabetes TrialNet is collaborating with the following NIH-funded groups, also conducting type 1 diabetes research:

Study Status Description
T1DGC No Longer Recruiting

The Type 1 Diabetes Genetics Consortium (T1DGC) is collecting blood samples and health information from African American and Mexican American individuals with type 1 diabetes, as well as from people who do not have type 1 or type 2 diabetes in their immediate family.

For more information, visit (www.t1dgc.org)


The Immune Tolerance Network is offering additional intervention studies. More information is available at www.immunetolerance.org.